Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $22.80.

Several equities research analysts recently commented on INMB shares. Scotiabank increased their price objective on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th. Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target for the company. Maxim Group increased their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th.

Institutional Investors Weigh In On INmune Bio

A number of hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in INmune Bio during the fourth quarter valued at $2,221,000. Geode Capital Management LLC lifted its position in shares of INmune Bio by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock valued at $1,698,000 after buying an additional 19,136 shares in the last quarter. Millennium Management LLC grew its stake in shares of INmune Bio by 43.9% during the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock valued at $1,360,000 after acquiring an additional 88,823 shares during the period. State Street Corp increased its holdings in INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after acquiring an additional 58,838 shares in the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in INmune Bio during the 4th quarter worth approximately $896,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Price Performance

INMB opened at $7.76 on Tuesday. INmune Bio has a 1 year low of $4.32 and a 1 year high of $11.76. The stock has a 50-day moving average price of $7.76 and a 200-day moving average price of $6.80. The firm has a market cap of $178.36 million, a PE ratio of -3.56 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.14. As a group, sell-side analysts anticipate that INmune Bio will post -2.24 EPS for the current year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.